ストックスクリーナーアプリを入手
0.49
0.43%
0.0021
アフターアワーズ：
.47
-0.02
-4.08%
前日終値:
$0.4879
開ける：
$0.48
24時間の取引高:
76,939
Relative Volume:
0.65
時価総額：
$12.83M
収益：
-
当期純損益:
$-26.56M
株価収益率:
-0.7538
EPS:
-0.65
ネットキャッシュフロー:
$-22.29M
1週間 パフォーマンス:
-5.51%
1か月 パフォーマンス:
-21.20%
6か月 パフォーマンス:
-31.01%
1年 パフォーマンス:
-88.28%
1日の値動き範囲:
$0.4611
$0.5081
1週間の範囲:
$0.4611
$0.5398
52週間の値動き範囲:
$0.4611
$4.60
BiomX Inc Stock (PHGE) Company Profile
名前
BiomX Inc
セクター
電話
972 7 23942377
住所
7 Pinhas Sapir Street, 2nd Floor, Ness Ziona
PHGE を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
PHGE
BiomX Inc
|
0.49 | 13.58M | 0 | -26.56M | -22.29M | -0.65 |
|
ONC
Beone Medicines Ltd Adr
|
245.58 | 26.10B | 3.81B | -644.79M | -669.77M | -6.24 |
|
VRTX
Vertex Pharmaceuticals Inc
|
442.05 | 111.96B | 11.10B | -988.90M | -1.26B | -3.92 |
|
AKTX
Akari Therapeutics Plc Adr
|
1.35 | 42.96M | 0 | 0 | 0 | 0.00 |
|
VRNA
Verona Pharma Plc Adr
|
81.20 | 6.39B | 0 | -153.72M | -103.81M | -2.00 |
|
REGN
Regeneron Pharmaceuticals Inc
|
490.28 | 63.52B | 14.09B | 4.50B | 2.96B | 39.28 |
BiomX Inc Stock (PHGE) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2021-04-15 | 開始されました | Ladenburg Thalmann | Buy |
BiomX Inc (PHGE) 最新ニュース
Biomx stock plunges to 52-week low, hitting $0.47 - Investing.com Australia
Biomx stock plunges to 52-week low, hitting $0.47 By Investing.com - Investing.com India
BiomX (NYSEMKT:PHGE) Stock Price Down 32.6% – What’s Next? - Defense World
BiomX CEO Jonathan Solomon to Present at Biomed Israel 2025 Conf - GuruFocus
BiomX Inc. to Present Positive Phase 2 Results for BX211 at Biomed Israel 2025 Conference - Nasdaq
BiomX CEO Jonathan Solomon to Present at Biomed Israel 2025 Conference - GlobeNewswire
BiomX Inc. (AMEX:PHGE) Q1 2025 Earnings Call Transcript - MSN
HC Wainwright Issues Pessimistic Forecast for BiomX (NYSEAMERICAN:PHGE) Stock Price - Defense World
BiomX Inc. Earnings Call: Optimism and Progress - TipRanks
PHGE: HC Wainwright & Co. Maintains Buy Rating, Lowers Price Tar - GuruFocus
BiomX (PHGE) Price Target Reduced by Analyst Yet Buy Rating Maintained | PHGE Stock News - GuruFocus
BiomX Inc (PHGE) Q1 2025 Earnings Call Highlights: Strategic Advances and Financial Resilience - Yahoo Finance
BiomX Inc. Reports Q1 2025 Progress and Financials - TipRanks
BiomX Inc. Reports Earnings Results for the First Quarter Ended March 31, 2025 - marketscreener.com
BiomX Inc. SEC 10-Q Report - TradingView
BiomX Reports First Quarter 2025 Financial Results and Provides Business and Program Updates - TradingView
BiomX Reports First Quarter 2025 Financial Results and Provides Business and Program Updates | PHGE Stock News - GuruFocus
BiomX Breakthrough: Phase 2 Trial Reveals 40% Superior Efficacy in Fighting Antibiotic-Resistant Infections - Stock Titan
BiomX (PHGE) to Release Quarterly Earnings on Thursday - Defense World
BiomX to Host First Quarter 2025 Financial Results Conference Call and Webcast on May 15, 2025 - GlobeNewswire
BiomX to Host First Quarter 2025 Financial Results Conference Call and Webcast on May 15, 2025 | PHGE Stock News - GuruFocus
BiomX Inc. to Host Conference Call for First Quarter 2025 Financial Results and Business Updates - Nasdaq
JPMorgan Chase & Co. Invests $314,000 in BiomX Inc. (NYSEMKT:PHGE) - Defense World
Short Interest in BiomX Inc. (NYSEAMERICAN:PHGE) Decreases By 48.2% - Defense World
BiomX (PHGE) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now - MSN
HC Wainwright Reiterates “Buy” Rating for BiomX (NYSEMKT:PHGE) - Defense World
Q1 Earnings Estimate for BiomX Issued By HC Wainwright - Defense World
What is HC Wainwright’s Estimate for BiomX FY2025 Earnings? - Defense World
What is HC Wainwright’s Forecast for BiomX Q1 Earnings? - Defense World
HC Wainwright Issues Positive Forecast for BiomX (NYSEAMERICAN:PHGE) Stock Price - Defense World
Earnings call transcript: Biomx Q1 2025 sees potential breakthrough in phage therapy By Investing.com - Investing.com South Africa
Earnings call transcript: Biomx Q1 2025 sees potential breakthrough in phage therapy - Investing.com India
Biomx stock plunges to 52-week low, hits $0.48 - Investing.com
Biomx stock plunges to 52-week low, hits $0.48 By Investing.com - Investing.com India
BiomX Announces Compliance with NYSE Guidelines on Audit Opinion Disclosure - GlobeNewswire
BiomX stock target soars to $21 on Phase 2 trial success - Investing.com India
BiomX Announces Positive Phase 2 Trial Results - TipRanks
BiomX reports progress in diabetic ulcer treatment By Investing.com - Investing.com Australia
BiomX reports progress in diabetic ulcer treatment - Investing.com India
BiomX Announces Positive Topline Results From Phase 2 Trial Evaluating Bx211 For The Treatment Of Diabetic Foot Osteomyelitis (DFO) - MarketScreener
BiomX Announces Positive Topline Results from Phase 2 Trial - GlobeNewswire
BiomX Inc (PHGE) 財務データ
収益
当期純利益
現金流量
EPS
1.89%
3.74%
大文字化:
|
ボリューム (24 時間):